{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:47:57Z","timestamp":1792277277364,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.tranon.2024.101943","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:28:00Z","timestamp":1712719680000},"page":"101943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach"],"prefix":"10.1016","volume":"44","author":[{"given":"Austin T.K.","family":"Hoke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Padget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-9074","authenticated-orcid":false,"given":"Jared","family":"Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-8298","authenticated-orcid":false,"given":"Patrick","family":"Soon-Shiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab Y.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-4407","authenticated-orcid":false,"suffix":"Jr","given":"Nyall R.","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tranon.2024.101943_bib0001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.18.00353","article-title":"Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma","volume":"37","author":"Amit","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOO.0000000000000513","article-title":"Oncologic management of sinonasal undifferentiated carcinoma","volume":"27","author":"Tyler","year":"2019","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"issue":"11","key":"10.1016\/j.tranon.2024.101943_bib0003","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1002\/hed.26357","article-title":"Sinonasal undifferentiated carcinoma: institutional trend toward induction chemotherapy followed by definitive chemoradiation","volume":"42","author":"London","year":"2020","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.pap.0000163958.29032.56","article-title":"Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis","volume":"12","author":"Ejaz","year":"2005","journal-title":"Adv. Anat. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11912-019-0776-4","article-title":"Sinonasal undifferentiated carcinoma","volume":"21","author":"Abdelmeguid","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.tranon.2024.101943_bib0006","first-page":"94","article-title":"Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States","volume":"76","author":"Chambers","year":"2015","journal-title":"J. Neurol. Surg. B Skull Base"},{"issue":"8 Pt 1","key":"10.1016\/j.tranon.2024.101943_bib0007","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00005537-200208000-00023","article-title":"Sinonasal undifferentiated carcinoma: the search for a better outcome","volume":"112","author":"Musy","year":"2002","journal-title":"Laryngoscope"},{"key":"10.1016\/j.tranon.2024.101943_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.oraloncology.2019.07.028","article-title":"Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma","volume":"97","author":"Takahashi","year":"2019","journal-title":"Oral Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2024.101943_bib0009","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/hed.25748","article-title":"Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma","volume":"41","author":"Takahashi","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0010","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1038\/s41467-022-34815-3","article-title":"DNA methylation-based classification of sinonasal tumors","volume":"13","author":"Jurmeister","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.tranon.2024.101943_bib0011","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41379-019-0285-x","article-title":"DNA methylation-based classification of sinonasal undifferentiated carcinoma","volume":"32","author":"Dogan","year":"2019","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.tranon.2024.101943_bib0012","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1055\/s-0039-1693659","article-title":"Loss of SMARCB1 expression confers poor prognosis to sinonasal undifferentiated carcinoma","volume":"81","author":"Chitguppi","year":"2020","journal-title":"J. Neurol. Surg. B Skull Base"},{"issue":"5","key":"10.1016\/j.tranon.2024.101943_bib0013","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/modpathol.2016.239","article-title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","volume":"30","author":"Jo","year":"2017","journal-title":"Mod. Pathol."},{"issue":"10212","key":"10.1016\/j.tranon.2024.101943_bib0014","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.tranon.2024.101943_bib0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2024.101943_bib0016","doi-asserted-by":"crossref","first-page":"NP101","DOI":"10.1177\/03008916211026971","article-title":"Complete response to immunotherapy in sinonasal undifferentiated carcinoma","volume":"107","author":"Denaro","year":"2021","journal-title":"Tumori"},{"issue":"9","key":"10.1016\/j.tranon.2024.101943_bib0017","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002128","article-title":"Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines5010007","article-title":"The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture","volume":"5","author":"Garrido","year":"2017","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.tranon.2024.101943_bib0021","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/curroncol28020105","article-title":"The advances and challenges of NK cell-based cancer immunotherapy","volume":"28","author":"Kang","year":"2021","journal-title":"Curr. Oncol."},{"issue":"23","key":"10.1016\/j.tranon.2024.101943_bib0022","doi-asserted-by":"crossref","first-page":"33498","DOI":"10.18632\/oncotarget.9256","article-title":"Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab","volume":"7","author":"Fujii","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2767-9764.CRC-21-0020","article-title":"Combinatorial natural killer cell-based immunotherapy approaches selectively target chordoma cancer stem cells","volume":"1","author":"Hoke","year":"2021","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0024","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2024.101943_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.oraloncology.2019.01.017","article-title":"Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells","volume":"90","author":"Friedman","year":"2019","journal-title":"Oral Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0026","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"23","key":"10.1016\/j.tranon.2024.101943_bib0027","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.tranon.2024.101943_bib0028","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.tranon.2024.101943_bib0029","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","article-title":"Rationale for IL-15 superagonists in cancer immunotherapy","volume":"20","author":"Knudson","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3892\/etm.2021.10107","article-title":"Therapeutic potential of interleukin-15 in cancer (Review)","volume":"22","author":"Isvoranu","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"22","key":"10.1016\/j.tranon.2024.101943_bib0031","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1158\/1078-0432.CCR-12-1876","article-title":"Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma","volume":"18","author":"Takahashi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.101943_bib0032","series-title":"Spatial Point Patterns: Methodology and Applications with R","author":"Baddeley","year":"2015"},{"issue":"9","key":"10.1016\/j.tranon.2024.101943_bib0033","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-22-1821","article-title":"Spatial transcriptomics depict ligand-receptor cross-talk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors","volume":"83","author":"Ferri-Borgogno","year":"2023","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2024.101943_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081924","article-title":"Using the R Package spatstat to assess inhibitory effects of microregional hypoxia on the infiltration of cancers of the head and neck region by cytotoxic T lymphocytes","volume":"13","author":"Kaufmann","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2024.101943_bib0035","unstructured":"Kassambara A. Pipe-friendly framework for basic statistical tests. R package version 0.7.2. 2023 [Available from: https:\/\/CRAN.R-project.org\/package=rstatix."},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0036","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2024.101943_bib0037","first-page":"147","article-title":"An IL-15 superagonist, ALT-803, enhances antibody-dependent cell-mediated cytotoxicity elicited by the monoclonal antibody NEO-201 against human carcinoma cells","volume":"34","author":"Fantini","year":"2019","journal-title":"Cancer Biother. Radiopharm."},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0038","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.29686","article-title":"Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model","volume":"138","author":"Mathios","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2024.101943_bib0039","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00262-019-02372-2","article-title":"An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck","volume":"68","author":"Pinette","year":"2019","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.tranon.2024.101943_bib0040","first-page":"73","article-title":"Natural killer cells: role in local tumor growth and metastasis","volume":"6","author":"Langers","year":"2012","journal-title":"Biologics"},{"issue":"5","key":"10.1016\/j.tranon.2024.101943_bib0041","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3171\/2017.1.JNS162610","article-title":"A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab","volume":"128","author":"Fujii","year":"2018","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.tranon.2024.101943_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2024.101943_bib0043","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bjc.2015.277","article-title":"Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma","volume":"113","author":"Oguejiofor","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2024.101943_bib0044","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jop.13055","article-title":"The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma","volume":"49","author":"Gurin","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.tranon.2024.101943_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104776","article-title":"Immune checkpoint inhibitors in sinonasal squamous cell carcinoma","volume":"109","author":"Park","year":"2020","journal-title":"Oral Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2024.101943_bib0046","first-page":"e3519","article-title":"The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent\/metastatic sinonasal cancer","volume":"10","author":"Yazici","year":"2018","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.tranon.2024.101943_bib0047","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/hed.25067","article-title":"Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer","volume":"40","author":"Riobello","year":"2018","journal-title":"Head Neck"},{"issue":"13","key":"10.1016\/j.tranon.2024.101943_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136926","article-title":"Prognostic and therapeutic implications of immune classification by CD8(+) tumor-infiltrating lymphocytes and PD-L1 expression in sinonasal squamous cell carcinoma","volume":"22","author":"Garcia-Marin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.tranon.2024.101943_bib0049","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.tranon.2024.101943_bib0050","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin. Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T10:03:54Z","timestamp":1714298634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":50,"alternative-id":["S1936523324000706"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101943","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101943"}}